MED · XBRL financial data

Medifast financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (MED's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	935	—	—	—	—	—
Revenue from contracts with customers	—	1,526	1,599	1,072	602	386
Cost of revenue	237	398	458	296	158	111
Gross profit	698	1,128	1,140	776	445	275
Research and development	3	4	5	5	5	4
Selling, general and administrative	564	911	956	649	442	289
Operating income (loss)	134	216	185	126	3	(14)
Other income (expense)	(0)	0	(0)	(0)	(4)	3
Income tax expense (benefit)	31	52	40	29	2	13
Net income (loss)	103	164	144	99	2	(19)
Earnings per share, basic USD per share	8.74	14.01	12.82	9.13	0.19	(1.70)
Earnings per share, diluted USD per share	8.68	13.89	12.73	9.10	0.19	(1.70)
Weighted average shares, basic millions of shares	12	12	11	11	11	11
Weighted average shares, diluted millions of shares	12	12	11	11	11	11

Fiscal years (MED's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	164	104	88	94	91	89
Short-term investments	11	5	0	56	71	78
Marketable securities	174	110	0	—	—	—
Accounts receivable	1	—	—	—	—	—
Inventory	53	180	119	55	42	20
Prepaid and other current assets	6	16	16	11	10	9
Total current assets	234	307	223	224	214	202
Property and equipment, net	28	56	57	51	38	31
Right-of-use asset	11	24	18	16	11	7
Total assets	276	398	316	310	284	248
Total current liabilities	111	170	141	92	64	43
Lease liability, non-current	7	26	20	16	10	6
Total liabilities	119	196	161	108	74	49
Retained earnings	154	190	140	175	177	158
Total stockholders' equity	157	202	155	201	210	199
Total liabilities and equity	276	398	316	310	284	248
Common shares outstanding (cover page) millions of shares	12	12	11	11	11	11

Fiscal years (MED's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	103	164	144	99	2	(19)
Stock-based compensation	7	10	11	8	7	8
Depreciation and amortization	7	7	11	13	13	14
Net cash from operating activities	145	95	195	148	24	7
Purchases of property and equipment	6	34	17	6	7	6
Net cash from investing activities	(1)	(29)	(11)	(61)	(27)	(8)
Share repurchases	5	56	126	4	0	0
Dividends paid	53	64	72	73	1	0
Net cash from financing activities	(57)	(125)	(200)	(80)	(2)	(1)
Net change in cash	87	(60)	(16)	7	(4)	(2)

SIC 2090 and related industry codes, similar size; rows marked “added: same SIC” fill a short list. Each row is the latest quarter reported.

How peers are chosen

SIC 2090 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Fewer than three companies fall in that range, so the list adds same-SIC (2090) companies nearest in public float, each marked “added: same SIC”.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “year only” links to a 10-K that gives only the full year: without all three earlier quarters there is no fourth quarter to work out, and the year total is never shown as a quarter.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Medifast	58	72	3.3*	11.2M	—	Q3 FY26 10-QSep 30, 2026
Farmer Brothers	4.2	89	(0.8)*	21.7M	5.3 quarters	Q2 FY26 10-QDec 31, 2025
Utz Brandsadded: same SIC	59	372	12*	not reported	—	Q2 FY26 10-QJun 28, 2026
Coffee Holdingadded: same SIC	2.9	22	1.1*	5.7M	—	Q3 FY26 10-QJul 31, 2026
McCormickadded: same SIC	331	2,025	168*	not reported	—	Q3 FY26 10-QAug 31, 2026
Top Wealth Group Holdingadded: same SIC	2.4	year only	year only	not reported	—	Q4 FY25 20-FDec 31, 2025

Not investment advice. Not affiliated with the U.S. SEC.